From the Guidelines
Irritable Bowel Syndrome (IBS) cannot be transmitted through anal intercourse or any other type of sexual activity. IBS is a functional gastrointestinal disorder characterized by chronic abdominal pain, bloating, and changes in bowel habits (constipation, diarrhea, or both) [ 1 ]. It is not caused by an infectious agent that can be passed from person to person. Rather, IBS is believed to result from a combination of factors including abnormal gut motility, visceral hypersensitivity, altered gut microbiome, psychological factors, and genetic predisposition.
Some key points to consider in the management of IBS include:
- The use of highly selective 5-HT 4 agonists, such as minesapride, which have been shown to improve symptoms in patients with IBS-C [ 1 ]
- The potential role of histamine in mediating visceral hypersensitivity, and the use of histamine 1 receptor antagonists, such as ebastine, in improving symptoms [ 1 ]
- The importance of considering the potential benefits and harms of different treatments, including the use of combination gut-brain neuromodulators, and the need for vigilance in monitoring for adverse effects, such as serotonin syndrome [ 1 ]
While certain infections (like gastroenteritis) can trigger IBS symptoms in some individuals (called post-infectious IBS), the syndrome itself is not contagious [ 1 ]. It's essential to note that while IBS isn't transmissible, sexually transmitted infections can be passed through unprotected anal sex, so using barrier methods like condoms is recommended to prevent STI transmission.
In terms of treatment, some interventions with reported efficacy for patients with undifferentiated IBS specifically classified as severe or refractory include cognitive behavioral therapy (CBT), integrative group therapy, gut-directed hypnotherapy, and gut-brain therapy [ 1 ]. However, the primary focus should always be on providing evidence-based care that prioritizes the patient's quality of life, morbidity, and mortality.